Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
clinical trials
3
×
inotersen
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
patisiran
3
×
san diego blog main
san diego top stories
tafamidis
alnylam pharmaceuticals
boston
drugs
fda
hereditary transthyretin amyloidosis
onpattro
pfizer
rna interference
san francisco blog main
san francisco top stories
vyndaqel
andrew fire
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
craig mello
dan ollendorf
john berk
john maraganore
mary o'donnell
neuropathy
new york
nobel prize
regeneron pharmaceuticals
What
alnylam
fda
ago
approved
drug
medicine
patients
afternoon
akcea
alnylam’s
amyloidosis
approve
attr
available
awaits
battle
biological
crossed
debilitating
decades
decision
discovered
disease
fingers
friday
genetic
gets
historic
history
landmark
making
medicines
ok
oks
onpattro
patisiran
pfizer
pharmaceuticals
rare
rna
Language
Current search:
patisiran
×
inotersen
×
" clinical trials "
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision